Greetings from Copenhagen, Denmark, where several members of the CureDuchenne team are attending the 24th International Annual Congress of the World Muscle Society (WMS). This is the largest annual international […]
Investment will help advance development of gene therapy technology offering resistance to pre-existing antibodies, enhanced gene delivery and the potential for repeat dosing. NEWPORT BEACH, CALIF. — (September 27, 2019) […]
View the Santhera Fall Update HERE.
View the Italfarmaco Fall Newsletter HERE.
Newport Beach, CA – (September 19, 2019) – CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Lianna Orlando, PhD […]
CureDuchenne Ventures is pleased to support Edgewise Therapeutics with innovative research for Duchenne. The Duchenne community needs multiple shots on goal and CureDuchenne continues to lead the way to impactful […]
The webinar will review the Italfarmaco Givinostat development program for Duchenne and Becker Muscular Dystrophy. Content that will be covered, includes: Updates from the EPIDYS Study, a phase 3 clinical […]
In rare diseases such as Duchenne, where the disease population is small, the drug development process can vary from that of more common diseases, and totally new treatment approaches such […]
NEWPORT BEACH, Calif. (September 10, 2019) – Finding the right mobility equipment for Duchenne muscular dystrophy patients can be a time intensive and frustrating process. To help take the guesswork […]
